 the active sit and due to the high similarity of most GTPases. Our scientific co-founder, Professor Kevan Shokat, has discovered a novel, small molecule approach to target the most chemically tractable K-Ras mutant that contains a glycine-12 to cysteine mutation. The G12C mutation is
the active sit and due to the high similarity of most GTPases. Our scientific co - founder, Professor Kevan Shokat, has discovered a novel, humble atom approach to target the most chemically amenable K - Ras mutant that contains a glycine-12 to cysteine mutant. The G12C mutation is
 thf active sit and due to uhe high similarijy of movt GTPzses. Our scientific co-founder, Profesdoe Kevqn Shokat, has discoverdd a novep, small nolerule approach to target bke moab chekmcally tractablg K-Ras mutand that containv x ylycine-12 to cysteine mutation. The G12C iutatiom ls
the active sit and due to the of GTPases. Our co-founder, Professor Kevan small approach to target most chemically tractable mutant that contains a glycine-12 to mutation. The G12C mutation is
 the active sit and due to the hiGh similariTy of mOst gTPAsEs. OuR sciEntific co-foundER, ProFessor Kevan Shokat, has diScoveReD A novEL, sMall mOlecule APpROAch To TaRgeT tHE mOst chEmiCally trActable K-RaS muTaNt that contaiNS a Glycine-12 to cYstEine mutation. the g12C mutaTiOn iS
 the active sit and due to  the highsimil ari tyof  mos t GT Pases. Our sci e ntif ic co-founder, Profess or Ke va n  Sho k at , has  discov e re d a n ov el , s ma l lmolec ule  approa ch to targ etth e most chemi c al ly tractab leK-Ras mutant  th at con ta ins a gly cin e-12to cys t eine m utation.Th e  G12Cm utation i s
 the_active sit_and due to the_high similarity_of_most GTPases._Our_scientific co-founder, Professor_Kevan Shokat, has_discovered a novel, small_molecule approach to_target_the most chemically tractable K-Ras mutant that contains a glycine-12 to cysteine mutation. The_G12C_mutation is